Background
==========

Ovarian cancer is one of the leading causes of cancer-related death in women today. It is the 4^th^most common cancer in women in Norway and accounts for 5 -- 6% of all cancers \[[@B1],[@B2]\]. Mean age at diagnosis for sporadic cases have been reported to 62.3 years \[[@B3]\], and in Norway to 65 years. Age-standardized incidence rates were 13.5 pr 100.000, and close to 40% of the patients is achieving 5-year survival according to The Norwegian Cancer Registry (OVANOR 1991 -- 1996).

Almost 10% of epithelial ovarian cancer cases are associated with dominant genetic predisposition, in most cases (80 -- 90%), linked to mutations in *BRCA1*or *BRCA2*\[[@B4]-[@B6]\]. Mean age at diagnosis for these inherited cases have been reported to be from 49 to 54.3 years \[[@B3],[@B7]\]. The penetrance of the disease in mutation carriers varies, and has been reported to be from 27 -- 80% \[[@B8]-[@B10]\]. It should be noted that both the incidence rate for hereditary cases and the penetrance of the disease may differ depending on geographic and ethnic origin \[[@B11]\]. The survival rate may also vary depending on type and localization of the mutation. Some studies have reported that ovarian cancer patients carrying germ-line *BRCA1*mutations have an enhanced survival rate compared to sporadic cases \[[@B3],[@B12]-[@B14]\]. Other studies demonstrated only an initial survival advantage that disappeared with time, and concluded that no enhanced survival rates follows *BRCA1*dysfunction \[[@B15]-[@B17]\]. These studies predict a survival rate for *BRCA1*familial ovarian cancer that is equal to or higher than non-familial cases.

Both the penetrance estimates and the survival rates are based on studies in populations with strong founder effects, and may therefore be biased. The type of mutation in the *BRCA1*gene may affect the timing of the diagnosis of the disease, the response to environmental exposure causing DNA damage, the efficiency of DNA repair, and the frequency of somatic mutations developing in the tumor. These factors may in turn affect the survival rate.

Mutations in the *TP53*tumor suppressor gene are the most common genetic alteration in human tumors and have been suggested as a molecular marker for prognosis. *TP53*encodes a nuclear phosphoprotein located at chromosome region 17p13 involved in cell cycle arrest and DNA repair and somatic *TP53*mutations are known to associate with familial ovarian cancer. In ovarian tumors from *BRCA1*mutation carriers, somatic *TP53*mutations are found in 60 -- 80% of the cases \[[@B18]-[@B22]\]. Thirty to 50% of all ovarian cancers have been reported to harbor a *TP53*mutation \[[@B18]-[@B20],[@B23],[@B24]\]. Further, in 30 -- 85% of the sporadic ovarian carcinomas both a *TP53*mutations and a somatic *BRCA1/BRCA2*mutation have been found \[[@B18],[@B20],[@B25]\].

These findings implicate that *TP53*and *BRCA1*directly interacts and may play an important role in DNA repair processes and tumor suppression \[[@B26],[@B27]\]. However, despite the high frequency of mutations in the tumor suppressor gene *TP53*, there are several reports concluding that *TP53*is not a good predictor of prognosis in sporadic ovarian cancer patients \[[@B24],[@B28],[@B29]\].

We have previously reported two Norwegian *BRCA1*founder mutations; 1135insA \[[@B30]\] and 1675delA \[[@B11]\]. Carriers of these mutations show almost the same penetrance for ovarian- and breast cancer and the penetrance is also high compared to most reported *BRCA1*mutation carriers. By age 50, 48% of mutation carriers had experienced breast- and/or ovarian cancer. Mean age of ovarian cancer diagnosis was \~55 years \[[@B10]\]. Three per cent of all Norwegian ovarian cancers are caused by either of the two founder mutations \[[@B31]\]. As a result of a clinical follow-up program for early diagnosis in women from breast-ovarian cancer kindreds, these two mutations may account for more than half of those with a *BRCA1*mutation in Norway. The histopathological characteristics of both breast and ovarian cancer indicated an unfavorable prognosis in these mutation carriers \[[@B32]\].

In the present study, we have screened epithelial ovarian tumors from 30 familial cases and 100 sporadic cases for somatic mutations in the *TP53*gene. The cancer treatment was according to our hospital protocol. The familial cases consisted of one group with the *BRCA1*1135insA mutation and the other had the *BRCA1*1675delA mutation \[[@B10]\]. The *TP53*mutation status was correlated to survival, age at diagnosis and histopathological features.

Materials
=========

Formalin fixed and paraffin embedded ovarian cancer tissue from 30 *BRCA1*germ line mutation carriers were collected and used for DNA extraction. Of the familial cases 20 patients carried the 1675delA mutation and another 10 patients the 1135insA mutation, which is a representative distribution between the two mutations in the Norwegian population. The *BRCA1*carriers were from families with at least two first-degree relatives, or second-degree relatives through male, with ovarian cancer and/or breast cancer under age 60. All cases were sampled from pedigree regardless of survival status, as ovarian cancer treatment is centralized to our hospital. Analysis of fresh frozen specimen of tumor DNA from the 100 sporadic cases sampled from 1992--2003, included in this study has previously been reported \[[@B29]\]. Both groups were diagnosed and treated at the Norwegian Radium Hospital according to protocol. The patient characteristics are shown in Table [1](#T1){ref-type="table"}. All tumors were reviewed at our department of pathology, the familial tumors by our team pathologist, and were classified and graded according to the World Health Organization (WHO) criteria. Follow-up time for each case was calculated from the date of diagnosis up to date of death or end of study (15^th^April, 2004).

Methods
=======

DNA extraction and *TP53*mutation analysis
------------------------------------------

DNA was manually extracted from paraffin-embedded tissue sections of tumor material using 5 sections of 10 μ. A modification of the procedure described by Miller \[[@B33]\] was used. The modification included using as much as possible of the top water layer of the 700 ml DNA/lysis buffer and 1 ml phenol/chloroform/water mix, and repeating the extraction step once. The protocol was optimized to give high yield of good quality DNA.

Mutation analyses of exons 2--11 of the *TP53*gene in the 30 cases with *BRCA1*germ line mutations were performed by TTGE followed by sequencing. Primers, PCR conditions and gel running conditions were as described elsewhere \[[@B34]\]. Samples with aberrantly migrating bands on TTGE were isolated, submitted to a new PCR and sequenced. Analysis of the fresh frozen specimen of tumor DNA from the 100 sporadic cases has previously been reported \[[@B29]\].

Statistical analyses
--------------------

In univariate analyses, a log rank test have been used to investigate the effect of age at diagnosis, *BRCA1*and *TP53*mutations on the survival rate. In multivariate analyses, Cox proportional hazards regression analysis was used. Hazard ratios (HR\'s) are given with 95% confidence intervals (CI\'s). Statistical significance rates were set at 0.05. The software SAS^®^version 8.2 was used for statistical analyses.

Results
=======

*TP53*characterizations and novel mutations
-------------------------------------------

Nineteen of the 30 ovarian carcinomas showed one or more aberrant migrating bands on TTGE in one or more exons and was sequenced (Table [2](#T2){ref-type="table"}). A total of 21 sequence changes were detected. Two cases had two different *TP53*sequence changes in their tumors, one being a silent mutation. Nine mutations were missense mutations, four nonsense, three were silent sequence changes (not previously reported as polymorphisms) and two were intronic sequence changes of unknown function.

The frequency of transitions vs. transversion in this hereditary cohort (85.7% and 14.3%) was also quite similar to that reported in the IARC database for sporadic cases (88% and 12%), but differed slightly from the sporadic cases in this study (76.4% and 23.6%). The frequency of mutations likely to cause protein alteration were 68.0% (68/100) for the sporadic cases and 53.3%(16/30) for the familial cases. The *TP53*mutation frequency in the two different *BRCA1*carriers differed slightly with 11/20 (55.0%) in the *BRCA1*1675delA carriers and 5/10 (50.0%) in the *BRCA1*1135insA carriers. The 1675delA carriers had 7.7% transversions and 92.3% transitions while the 1135insA carriers had 12.5% transversion and 82.5% transitions. Four of the *TP53*mutations were novel and not previously reported in ovarian cancer in the IARC *TP53*Database \[[@B35]\] or the SOUSSI database. These mutations affected codon 205 (tyr\>ser), 260 (ser\>ser), 267 (arg\>gln) and 293 (gly\>arg). All mutations detected resided in exons 5--8. When comparing the *TP53*mutation spectrum in these familial cases with that of ovarian cancers cases reported in the IARC database and to the 100 sporadic ovarian cancer cases with a *TP53*mutation, no obvious differences were seen either with respect to exon distribution or codon wise (data not shown), although a slightly lower frequency of mutations in exon 5 and a slightly higher in exon 8 were seen in the hereditary cases. The *TP53*mutations in the 100 sporadic cases used in this study is reported elsewhere \[[@B29]\].

Age at diagnosis, survival, *BRCA1*and *TP53*status
---------------------------------------------------

Median age at diagnosis among sporadic cases and familial cases that carried 1675delA or 1135insA mutations is presented in Table [1](#T1){ref-type="table"}. As expected, the familial cases are diagnosed earlier in life than sporadic cases (p \< 0.001). The difference in median age of onset between the 1135insA and 1675delA mutation carriers was not significant (p = 0.245).

In the univariate analysis of the combined group, neither *BRCA1*status nor age at diagnosis was significantly associated to survival (p = 0.87 and p = 0.50 for *BRCA1*status and age at diagnosis (categorized into \< 50 and ≥ 50 years), respectively). *TP53*mutation did not significantly reduce the survival rates (p = 0.35). Notably, interaction between *BRCA1*status and *TP53*status was borderline significant (test for interaction: p = 0.06) while the one between *BRCA1*status and age at diagnosis was statistically significant (test for interaction: p = 0.05). We further analyzed these factors adjusted for tumor grade, however, results did not substantially change (test interaction: p = 0.04 and p = 0.05 for BRCA1\*TP53 and BRCA1\*age at diagnosis, respectively).

No association between age at diagnosis and survival time was found among sporadic cases (p = 0.88). Familial cases with late age at diagnosis (≥50 years) had a slightly higher risk of dying than the cases with an early age at diagnosis, however the association did not reach significance, possibly due to a lack of statistical power (RR = 1.65, 95% CI \[0.79--3.43\], p = 0.14). Among cases diagnosed at age 50 years or more, familial cases had a trend towards a higher risk of dying than sporadic cases (RR = 1.75, 95% CI \[0.93--3.30\], p = 0.08). After adjustment for the effect of tumor grade and *TP53*status (RR = 1.80, 95% CI \[0.94--3.43\], p = 0.08) (data not shown). Table [3](#T3){ref-type="table"} shows the risk ratios associated to *TP53*mutations after stratification for *BRCA1*status.

There was no significant difference in survival observed among *TP53*mutations carriers compared to non-*TP53*mutations carriers, neither for the familial nor the sporadic cases (Log-rank test for *TP53*in familial cases: p = 0.25 and log-rank test for *TP53*in sporadic cases: p = 0.88) (Table [3](#T3){ref-type="table"}).

Discussion
==========

Some studies have reported an enhanced survival for *BRCA1*carriers with ovarian cancer compared to sporadic cases \[[@B12]-[@B14],[@B36],[@B37]\], but these studies have not taken *TP53*status in the tumors in to consideration. Other studies in which *TP53*status have been included concludes that there is no difference in survival \[[@B16]\].

Our results do not show an enhanced survival rate for familial cases compared to sporadic cases, even after adjustment for *TP53*status when all age groups were included. Further, no significant difference in survival rates was observed between the familial cases with and without *TP53*mutations (Table [3](#T3){ref-type="table"}).

These results **do not**support earlier observations regarding the importance of the p53/BRCA1 interaction on cell proliferation and ovarian carcinogenesis. Most penetrance estimates and survival rates are based on studies in populations with strong founder effects, and may therefore be biased \[[@B15]-[@B17],[@B38]\]. Two Ashkenazi founder mutations occur in *BRCA1*185delAG and 5382insC (carrier frequencies of 0.9% and 0.13%), with mean age at diagnosis 54 years. How the type of mutation in the *BRCA1*gene affects survival, age at diagnosis of the disease, the response to environmental exposure causing DNA damage, and the efficiency of DNA repair, is not clarified. Heterozygote advantage or an increase in biological fitness conferred on carriers of a disease causing mutation (like *BRCA1*?), often a resistance to certain infections that were common in times past, can cause an increase in allele frequency \[[@B39]\]. Genetic factors with impact on survival and age at onset of disease, to after childbearing age, would be preferential.

The trend for an increased survival in favour of the early age at onset in familial cases compared to late age at onset in familial cases may be attributed to younger patients having greater physical strength, less somatic mutations, and manage illness better than older patients. On the other hand, one might also expect this trend in sporadic cases, which was not the case. One limitation of our study is the small numbers of *BRCA1*carriers. In our study, the statistical power to detect *BRCA1*effect was 76%.

Consequently, our findings should be confirmed in larger studies. The conflicting literature on the impact of *BRCA1*mutation status on ovarian cancer survival should promote additional studies from different ethnic populations, and thereby allow investigators to study whether or not there is a survival benefit due to *BRCA1*mutation, or may be secondary to other common inherited genetic factors, which may be shared in ethnic or geographic isolated populations.

Alterations in the *TP53*gene have been shown to affect breast cancer survival and in particular patients with mutations in the zinc-binding domains have poor survival \[[@B40]\]. In sporadic ovarian carcinoma several studies reports that no or little effect of *TP53*mutations have been seen \[[@B17],[@B24],[@B28]\], which is similar to the results reported here. *TP53*alterations are also suggested to alter ovarian cancer survival in *BRCA1*germ line patients \[[@B13],[@B14]\], while other groups concludes with a failure of *BRCA1*dysfunction to alter ovarian cancer survival \[[@B16]\]. It should also be noted that a considerable fraction (60--80%) of all familial *BRCA1*ovarian cancers harbor *TP53*mutations \[[@B18],[@B19],[@B21],[@B22]\]. Only a few studies have reported analysis of *TP53*mutations in relation to *BRCA1*associated ovarian cancer \[[@B20],[@B41]\]. The present study is the first investigating somatic *TP53*mutations in ovarian tumors from carries of two distinct high penetrant *BRCA1*germ-line mutations, relating it to survival and age at diagnosis of disease and compares it to sporadic cases. We have previously studied the distribution in age at diagnosis in *BRCA1*carriers and non-carriers as a part of a cohort study. Three percent of Norwegian ovarian cancers are caused by *BRCA1*1675delA or 1135insA \[[@B31],[@B42]\], with a distribution similar to that found in this study (Table [1](#T1){ref-type="table"}). Further, Bjørge et al. \[[@B43]\] found that 87.0% of Norwegian sporadic ovarian cancers was papillary serous adenocarcinoma, an aggressive histo-prognostic factor.

Eigthy percent of both familial and sporadic ovarian cancer cases in this study were papillary serous adenocarcinoma. Questions need to be addressed concerning the clinical effects of mutations in the *BRCA1*gene, why some mutation carriers develop breast cancer, others develop ovarian cancer, and some develop both. We do not know whether the cancers occurring in mutation carriers are significantly different from those occurring in non carriers. The frequency of *TP53*mutations in the familial cases altering the protein was 53.3%, which is somewhat higher than other studies of familial *BRCA1*ovarian cancer (31--50%) \[[@B18]-[@B22],[@B24],[@B25]\]. Although the number of familial cases in this study is limited, a slightly higher frequency of mutations was found in exon 8 and a lower frequency in exon 5 compared to sporadic cases in the IARC database. The same tendency has been reported by others \[[@B20]\]. However, a non-significant difference in *TP53*mutation frequency was observed between the familial and sporadic cases in this study.

Of the novel mutations found in the familial cohort the codon 205 mutation has previously been reported in several other tumors like head and neck SCC as well as breast- and colorectal carcinoma. The amino acid change in codon 255 and 293 are only reported once, in oesophageal SCC and bladder cancer, respectively. The silent codon 260 mutation are reported in two different cancer tissues; lung (SCLC) and colorectal carcinoma. Environmental exposure, both external and internal, is known to influence the spectrum of mutations. Whether hormonal disturbance may affect the mutation rate and spectrum is not known, but if so, it may be expected that *BRCA1*carriers are more sensitive to such exposure.

Conclusion
==========

Interestingly, no difference in survival was observed between *TP53*mutation carriers among the familial carries or among the sporadic cases (Table [3](#T3){ref-type="table"}). Further, we did not find an overall difference in survival between familial *BRCA1*carriers and sporadic epithelial ovarian cancer cases, even after adjustment for *TP53*status. For cases diagnosed over the age 50 there was a trend toward higher survival for sporadic cases.
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###### 

Patient characteristics

                             Sporadic cases   *BRCA1*carriers               
  -------------------------- ---------------- ----------------- ----------- ------------
  No of cases                100              30                10          20
  Age at diagnosis: Median   59               49                52.5        47
  range                      39 -- 80         39 -- 80          41 -- 80    39 -- 65
                                                                            
  FIGO stage                                                                
    I -- II                  9 (9.0%)         8 (26.7%)         2 (20.0%)   6 (30.0%)
    III                      65 (65.0%)       14 (46.7%)        5 (50.0%)   9 (45.0%)
    IV                       26 (26.0%)       8 (26.7%)         3 (30.0%)   5 (25.0%)
                                                                            
  Histology                                                                 
    Serous                   82 (82.0%)       24 (80.0%)        7 (70.0%)   17 (85.0%)
    Mixed                    7 (7.0%)         2 (6.6%)          1 (10.0%)   1 (5.0%)
    Endometroid              5 (5.0%)         3 (10.0%)         1 (10.0%)   2 (10.0%)
    Unclassified             6 (6.0%)         1 (3.3%)          1 (10.0%)   0
                                                                            
  Grade of differentiation                                                  
    1                        7 (7.0%)         0                 0           0
    2                        26 (26.0%)       5 (16.6%)         1 (10.0%)   4 (20.0%)
    3                        67 (67.0%)       24 (80.0%)        9 (90.0%)   15 (75.0%)
  Unknown                    0                1 (3.3%)          0           1 (5.0%)
                                                                            
  Survival \>5 years         23 (23.0%)       10 (33.3%)        3 (30.0%)   7 (35.0%)
                                                                            
  *TP53*mutation status      72.0%            53.3%             50.0%       55.0%

All tumors are epithelial adenocarcinomas

###### 

*TP53*mutations, survival and histopathological features for each case.

  Case       ^a^*BRCA1*carrier type   Stage   ^b^Grade   Type   TTGE   Exon   Codon    Mutation    aa change   Age of diagnosis   ^c^Survival months   ^d^Vital status
  ---------- ------------------------ ------- ---------- ------ ------ ------ -------- ----------- ----------- ------------------ -------------------- -----------------
  3453       1                        3       2          ser    pos    5               559+1G\>A   splice      53                 83                   1
  **10**     1                        3       3          ser    pos    6      213      CGA\>TGA    arg\>stop   65                 22                   **3**
  2857       1                        3       3          ser    pos    6      213      CGA\>TGA    arg\>stop   53                 83                   3
  **4**      1                        4       3          ser    pos    6      216      GTG\>ATG    val\>met    59                 11                   **3**
  **27**     1                        2       3          endo   pos    7      237      ATG\>ATA    met\>ile    39                 61                   **3**
  **8^e^**   1                        3       3          ser    pos    7      260      TCC\>TCT    ser\>ser    49                 84                   **3**
                                                                       8      306      CGA\>TGA    arg\>stop                                           
  **14**     1                        1       3          ser    pos    8      267      CGG\>CAG    arg\>gln    51                 25                   **3**
  **13**     1                        4       3          ser    pos    8      273      CGT\>AGT    arg\>ser    39                 15                   **3**
  **29**     1                        3       3          mix    pos    8      273      CGT\>TGT    arg\>cys    50                 36                   **3**
  2842       1 1                      4       3          ser    pos    8      273      CGT\>TGT    arg\>cys    39                 35                   3
  **21**     1                        3       3          ser    pos    8      293      GGG\>AGG    gly\>arg    39                 21                   **3**
  **26**     1                        3       2          ser    pos           intron   G\>A        ivs5        53                 93                   **1**
  **9**      1                        4       2          ser    neg                                            50                 39                   **3**
  **11**     1                        3       3          ser    neg                                            44                 8                    **3**
  **17**     1                        3       3          ser    neg                                            47                 30                   **3**
  **24**     1                        2       4          ser    neg                                            59                 20                   **3**
  **34**     1                        1       3          ser    neg                                            46                 120                  **1**
  **30**     1                        1       2          ser    neg                                            43                 199                  **2**
  **32**     1                        2       3          ser    neg                                            48                 108                  **1**
  **3351**   1                        4       3          endo   neg                                            44                 9                    **3**
  **1**      2                        4       3          ser    pos    5      144      CAG\>TAG    gln\>stop   41                 1                    **3**
  **3**      2                        3       3          uncl   pos    6      196      CGA\>TGA    arg\>stop   48                 46                   **3**
  **20**     2                        3       3          ser    pos    6      205      TAT\>TCT    tyr\>ser    52                 36                   **3**
  **28**     2                        4       3          ser    pos    7      261      AGG\>AGA    arg\>arg    80                 12                   **3**
  **7^e^**   2                        3       3          ser    pos    7      255      ATC\>GTC    ile\>val    58                 30                   **3**
                                                                       5      141      TGC\>TGT    cys\>cys                                            
  **12**     2                        1       3          ser    pos    8      280      AGA\>GGA    arg\>gly    49                 134                  **1**
  **15**     2                        3       3          ser    pos           intron   C\>T        ivs7        50                 19                   **3**
  **5**      2                        4       3          ser    neg                                            60                 45                   **3**
  **18**     2                        2       3          endo   neg                                            44                 117                  **3**
  **22**     2                        3       2          mix    neg                                            47                 96                   **3**

a: 1 = 1675delA and 2 = 1135insA. b: undifferentiated (4). c: all patients were followed until diseased or to 15^th^April, 2004. d: alive without cancer (1), alive with cancer (2), and dead by cancer (3). e: two different mutations detected in sample.

###### 

Hazard risk of *TP53*mutations on familial and sporadic ovarian cancer cases.

                        \# cases   HR        CI (95%)       p-value
  --------------------- ---------- --------- -------------- ---------
  Familial Cases        30                                  
    *TP53*no mutation   14         1 (ref)                  
    *TP53*mutation      16         1.64      0.71 -- 3.78   0.25
  Sporadic cases        100                                 
    *TP53*no mutation   26         1 (ref)                  
    *TP53*mutation      76         0.96      0.55 -- 1.66   0.88
